Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator
Xintela (XINT) announces that Xintela’s oncology subsidiary, Targinta AB, has today initiated a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator in New York, USA, for development of its integrin α10β1 antibody therapeutic in patients with aggressive sarcoma. Under the collaboration, Targinta will produce antibodies targeting integrin α10β1 and complete preclinical development work […]
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of […]
Xintela AB Interim Report January – June 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupSecond quarter 2025Income amounted to TSEK 872 (4).Loss before tax totalled TSEK 12,119 (loss: 10,400).Loss per share was SEK 0.02 (loss: 0.02). First half year 2025Income amounted to TSEK 1,012 (303).Loss before tax totalled TSEK 22,780 (loss: 21,773).Loss […]
Xintela strengthens management team with Peter Ekolind as COO & VP Commercial Manufacturing
Xintela announces the appointment of Peter Ekolind as Chief Operating Officer (COO) and Vice President Commercial Manufacturing. Peter started his position on August 18, 2025.With this recruitment, Xintela reinforces its focus on the company’s GMP manufacturing facility, a strategic asset for the commercial production of cell therapy products as well as for the supply of […]
Xintela completes clinical study with XSTEM in knee osteoarthritis
Xintela’s clinical study with XSTEM in knee osteoarthritis has been completed with the last follow-up visit for the last patient. Xintela previously communicated positive interim results up to 18 months after treatment and now completed the collection of 24-months data for the highest dose level. The final results of the study are planned to be reported […]
Xintela AB changes Certified Adviser to Tapper Partners AB
Xintela AB announces today that the company is changing its Certified Adviser to Tapper Partners AB. Xintela AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will […]
Xintela AB Interim Report January – March 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 10,427 (loss: 10,997).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 8,574 (loss: 9,688). Significant […]
Xintela AB publishes Annual Report 2024
Xintela AB (publ) announces that the company’s annual report for 2024 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]
Xintelling No. 6 2025
Read Xintela´s newsletter in English here Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products
Xintela and EQGen Biomedical Inc. (“EQGen”) have signed the definitive collaboration and license agreement, contemplated by their previously announced term sheet, for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and […]
